Results 241 to 250 of about 1,906,742 (351)

Caractérisation du trafic vésiculaire du récepteur tyrosine kinase AXL, et de son impact dans le cancer du sein triple négatif

Apcher, Chloé
openalex   +1 more source

Protein tyrosine kinase PYK2 involved in Ca2+-induced regulation of ion channel and MAP kinase functions

Nature, 1995
S. Lev, H. Moreno, R. Martinez, P. Canoll, E. Peles, J. Musacchio, G. Plowman, B. Rudy, J. Schlessinger   +8 more
semanticscholar   +1 more source

Chaperone‐Mediated Autophagic Degradation of USP9X in Macrophages Exacerbates Postmyocardial Infarction Inflammation and Cardiac Dysfunction

Advanced Science, EarlyView.
This study demonstrates that inflammatory stimuli induce the acetylation‐triggered, chaperone‐mediated autophagic degradation of ubiquitin‐specific peptidase 9 X‐linked (USP9X) in macrophages. USP9X acts as a macrophage “inflammation switch” after myocardial infarction (MI). USP9X loss destabilizes tumor necrosis factor receptor‐associated factor (TRAF)
Biqing Wang, Xiangheng Cai, Mengqi Li, Xue Liu, Junhui Xue, Ye Liu, Ding Ai, Xinyang Hu   +7 more
wiley   +1 more source

Longitudinal analysis of usage and public awareness of tyrosine kinase inhibitors for CML. [PDF]

Front Oncol
Schroer AE, Javadi T, Mehta A, Torlak F, McFarland JR, Kumar G, da Silva AL, Benjamin J, Choudhary MM, Sadeghi A, le Coutre P, Blaha MJ, Berning P, Dzaye O.   +13 more
europepmc   +1 more source

Functional coupling of the src-family protein tyrosine kinases p59fyn and p53/56lyn with the interleukin 2 receptor: implications for redundancy and pleiotropism in cytokine signal transduction.

, 1993
Naoki Kobayashi, Takahiro Kono, Masatsugu Hatakeyama, Y Minami, Tamana Miyazaki, Roger M. Perlmutter, Tatsuya Taniguchi   +6 more
openalex   +2 more sources

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma. [PDF]

Blood Adv
Phillips T, Di M, Miller TA, Wang J, Pierre A, Maglinte GA, Seymour EK, Wang Y.   +7 more
europepmc   +1 more source

Tyrosine kinases modulate K⁺ channel gating in mouse Schwann cells

, 1999
Asher Peretz, Alex Sobko, Bernard Attali
openalex   +2 more sources

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Cancer Research, 2004
S. Wilhelm, Christopher A. Carter, L. Tang, D. Wilkie, Angela Mcnabola, H. Rong, Charles Chen, Xiaomei Zhang, P. Vincent, M. McHugh, Yichen Cao, Jaleel Shujath, S. Gawlak, Deepa Eveleigh, B. Rowley, Li Liu, Lila Adnane, M. Lynch, D. Auclair, I. Taylor, R. Gedrich, A. Voznesensky, B. Riedl, L. Post, G. Bollag, P. Trail   +25 more
semanticscholar   +1 more source

Targeting PRKCN, an Essential Driver Orchestrating mTOR‐IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma

Advanced Science, EarlyView.
Constitutive PRKCN expression is driven by super‐enhancers and modulated by NF‐κB signaling in multiple myeloma (MM). PRKCN activates mTORC1/2‐IRF4 signaling axis and favors tumor cell growth independently of its kinase activity. IRF4 reciprocally promotes PRKCN transcription, creating a feed‐forward loop.
Koukou Tang, Dongpeng Jiang, Peng Ke, Xiaosen Bian, Lili Zhang, Ying Zhang, Tingting Zhu, Weiwei Qu, Wenhui Qi, Yang Xu, Chengcheng Fu, Depei Wu, Jianhong Chu   +12 more
wiley   +1 more source